[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![mupdatesbyscanx Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1926935883384553472.png) Market Updates by ScanX [@mupdatesbyscanx](/creator/twitter/mupdatesbyscanx) on x XXX followers
Created: 2025-07-22 11:59:40 UTC

Dr Reddys Laboratories (DRREDDY)
on NSE: 1240.00 (-1.53%)

Dr Reddy's Q1 Results Preview: Analysts Expect Revenue Growth Up to 19%, FDA Inspection Concludes Positively

View: Positive

Dr Reddy's Laboratories is set to announce Q1 results on July XX. Analysts project mixed earnings with PAT estimates ranging from ₹1,399.00 crore to ₹1,659.00 crore, and revenue estimates between ₹8,491.00 crore and ₹9,094.00 crore. Growth drivers include steady domestic demand, strong US sales, Nicotinell acquisition, and favorable currency movements. The company received a positive FDA inspection outcome for its API facility in Middleburgh, New York, classified as 'Voluntary Action Indicated'.

Read more:

#Stocks #Market #DRREDDY

![](https://pbs.twimg.com/media/Gwdc-5yWcAAdl7o.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947627602350641447/c:line.svg)

**Related Topics**
[quarterly earnings](/topic/quarterly-earnings)
[$drreddyns](/topic/$drreddyns)
[dr reddys](/topic/dr-reddys)

[Post Link](https://x.com/mupdatesbyscanx/status/1947627602350641447)